Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

AmberGen pioneers new Bead Array Mass Spectrometry Technology (Bead-AMS™) and is awarded 3 U.S. patents providing broad coverage

AmberGen awarded 3-year Phase II SBIR grant from NIH-NIGMS to develop Bead-AMS™ for screening on- and off-target drug binding on a proteome-wide scale

AmberGen awarded Phase I SBIR grant from NIH-NCI IMAT program to develop PC-PURE™ for the detection of serological ovarian cancer biomarkers

Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding

https://www.ncbi.nlm.nih.gov/pubmed/27194112

AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH

https://www.ncbi.nlm.nih.gov/pubmed/25243383